MX2022000827A - Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico. - Google Patents

Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico.

Info

Publication number
MX2022000827A
MX2022000827A MX2022000827A MX2022000827A MX2022000827A MX 2022000827 A MX2022000827 A MX 2022000827A MX 2022000827 A MX2022000827 A MX 2022000827A MX 2022000827 A MX2022000827 A MX 2022000827A MX 2022000827 A MX2022000827 A MX 2022000827A
Authority
MX
Mexico
Prior art keywords
hydroxybenzoyl
glp
agonist
amino
salt
Prior art date
Application number
MX2022000827A
Other languages
English (en)
Inventor
Patrick William Garibay
Andreas Vegge
Betty Lomstein Pedersen
Birgitte Nissen
Kaisa Naelapää
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2022000827A publication Critical patent/MX2022000827A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La invención se refiere a composiciones farmacéuticas sólidas que comprenden un agonista del GLP-1, un inhibidor del SGLT2 y una sal del ácido N-(8-(2-hidroxibenzoil)amino)caprílico. La invención se refiere, además, a procesos para la preparación de tales composiciones, y sus usos en medicina.
MX2022000827A 2019-08-07 2020-08-06 Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico. MX2022000827A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19190623 2019-08-07
EP20172415 2020-04-30
PCT/EP2020/072106 WO2021023811A1 (en) 2019-08-07 2020-08-06 Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid

Publications (1)

Publication Number Publication Date
MX2022000827A true MX2022000827A (es) 2022-02-16

Family

ID=71894842

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000827A MX2022000827A (es) 2019-08-07 2020-08-06 Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico.

Country Status (15)

Country Link
US (1) US20220265777A1 (es)
EP (1) EP4009941A1 (es)
JP (1) JP2022545156A (es)
KR (1) KR20220044269A (es)
CN (1) CN114173766A (es)
AU (1) AU2020325708A1 (es)
BR (1) BR112022000490A2 (es)
CA (1) CA3144611A1 (es)
CL (1) CL2022000137A1 (es)
CO (1) CO2022000578A2 (es)
IL (1) IL289504A (es)
MX (1) MX2022000827A (es)
PE (1) PE20220751A1 (es)
TW (1) TW202114730A (es)
WO (1) WO2021023811A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR112015A1 (es) * 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
MX2020007598A (es) * 2018-02-02 2020-09-03 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.
CN117580583A (zh) * 2021-06-25 2024-02-20 甘李药业股份有限公司 Pcsk9抑制剂和glp-1受体激动剂的药物组合
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
CN114085203A (zh) * 2021-12-17 2022-02-25 宁波高新区美诺华医药创新研究院有限公司 达格列净组合物
WO2023123063A1 (en) * 2021-12-29 2023-07-06 Guangzhou Dazhou Biomedicine Ltd. Oral delivery
CN116370609B (zh) * 2023-06-01 2023-08-15 北京普诺旺康医药科技有限公司 包含血管活性肠肽和吸收增强剂的固体组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN105503802A (zh) * 2016-01-15 2016-04-20 中山大学 一种达格列净-柠檬酸共晶的制备方法
WO2018124497A1 (ko) * 2016-12-30 2018-07-05 한미약품 주식회사 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
AR112015A1 (es) * 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral

Also Published As

Publication number Publication date
PE20220751A1 (es) 2022-05-10
BR112022000490A2 (pt) 2022-03-08
CN114173766A (zh) 2022-03-11
WO2021023811A1 (en) 2021-02-11
JP2022545156A (ja) 2022-10-26
CO2022000578A2 (es) 2022-04-29
KR20220044269A (ko) 2022-04-07
EP4009941A1 (en) 2022-06-15
CA3144611A1 (en) 2021-02-11
IL289504A (en) 2022-02-01
US20220265777A1 (en) 2022-08-25
CL2022000137A1 (es) 2022-10-07
TW202114730A (zh) 2021-04-16
AU2020325708A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
PH12020551066A1 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
MX2022000827A (es) Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico.
PH12020551691A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
MX2022013612A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX345501B (es) Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
WO2017180917A3 (en) Lipid compositions and their uses for intratumoral polynucleotide delivery
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2022004718A (es) Omposiciones sólidas que comprenden un inhibidor de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
MX353067B (es) Composiciones de peptidos de glp-1 y preparaciones de las mismas.
CL2010000434A1 (es) Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.
MX2021002981A (es) Pirrolinas fusionadas que actuan como inhibidores de la proteasa 30 especifica de la ubiquitina (usp30).
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PH12017502322A1 (en) Therapeutic agent for fibrosis
BR112021020883A2 (pt) Formas sólidas de um inibidor de glyt1
MX2022000889A (es) Composiciones solidas que comprenden un derivado de egf(a) y una sal de acido n-(8-(2-hidroxibenzoil)amino)caprilico.
MX2017010666A (es) Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico.
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα